A Phase I Dose‐Escalation Study of Linsitinib (OSI‐906), a Small‐Molecule Dual Insulin‐Like Growth Factor‐1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer

Lessons Learned The maximum tolerated dose of the combination of linsitinib and irinotecan is linsitinib 450 mg daily on days 1–3 every 7 days and irinotecan 125 mg/m2 days 1 and 8 of a 21‐day cycle. The adverse effects associated with the combination are not significantly increased beyond what is e...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2018-12, Vol.23 (12), p.1409-e140
Hauptverfasser:	Davis, S. Lindsey, Eckhardt, S. Gail, Diamond, Jennifer R., Messersmith, Wells A., Dasari, Arvind, Weekes, Colin D., Lieu, Christopher H., Kane, Madeline, Choon Tan, Aik, Pitts, Todd M., Leong, Stephen
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Clinical Trial Results Female Humans Imidazoles - pharmacology Imidazoles - therapeutic use Insulin-Like Growth Factor I - drug effects Irinotecan - pharmacology Irinotecan - therapeutic use Male Middle Aged Pyrazines - pharmacology Pyrazines - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!